APRE (Aprea Therapeutics) Cash Flow for Dividends: $0.00 Mil (TTM As of Mar. 2026)


APRE Aprea Therapeutics Inc APRE
30 GF Score
Price $0.80
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics Cash Flow for Dividends?

Aprea Therapeutics APRE -1.03% 30 Cash Flow for Dividends is $0.00 Mil as of Mar. 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Aprea Therapeutics's cash flow for dividends for the three months ended in Mar. 2026 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Aprea Therapeutics Cash Flow for Dividends Related Terms

Aprea Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Aprea Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprea Therapeutics Cash Flow for Dividends Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aprea Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
APRE
30GF Score
Aprea Therapeutics Inc APRE
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aprea Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $0.00 Mil mean?
Aprea Therapeutics (APRE) has a Cash Flow for Dividends of $0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Aprea Therapeutics and its competitors.
Is Aprea Therapeutics' Cash Flow for Dividends too high?
Aprea Therapeutics' current Cash Flow for Dividends is $0.00 Mil. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' Cash Flow for Dividends compare to JUNS and KAPA?
Aprea Therapeutics' Cash Flow for Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Aprea Therapeutics and its competitors. Aprea Therapeutics's current Cash Flow for Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current Cash Flow for Dividends of $0.00 Mil. The current Cash Flow for Dividends is $0.00 Mil. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current Cash Flow for Dividends is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score

Get the complete analysis for APRE

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.80
Price